Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Herrmann K, Eiber M, Fendler WP, Delpassand E. Calais J, et al. Among authors: ranganathan d. J Nucl Med. 2021 Oct;62(10):1447-1456. doi: 10.2967/jnumed.121.262543. Epub 2021 Jul 16. J Nucl Med. 2021. PMID: 34272322 Free PMC article. Clinical Trial.
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort.
Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Ranganathan D, Slavik R, Dahlbom M, Herrmann K, Delpassand E, Fendler WP, Czernin J. Calais J, et al. Among authors: ranganathan d. J Nucl Med. 2021 Oct;62(10):1440-1446. doi: 10.2967/jnumed.121.261982. Epub 2021 May 20. J Nucl Med. 2021. PMID: 34016732 Free PMC article. Clinical Trial.
64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial.
Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, Kjaer A, Tworowska I, Núñez R. Delpassand ES, et al. Among authors: ranganathan d. J Nucl Med. 2020 Jun;61(6):890-896. doi: 10.2967/jnumed.119.236091. Epub 2020 Jan 10. J Nucl Med. 2020. PMID: 31924723 Free article. Clinical Trial.
Microfluidic radiolabeling of biomolecules with PET radiometals.
Zeng D, Desai AV, Ranganathan D, Wheeler TD, Kenis PJ, Reichert DE. Zeng D, et al. Among authors: ranganathan d. Nucl Med Biol. 2013 Jan;40(1):42-51. doi: 10.1016/j.nucmedbio.2012.08.012. Epub 2012 Oct 15. Nucl Med Biol. 2013. PMID: 23078875 Free PMC article.
143 results